Spots Global Cancer Trial Database for Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
Official Title: Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
Study ID: NCT02032784
Conditions
Study Description
Brief Summary: Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
Detailed Description: Inclusion Criteria: Duodenal or ampullary adenoma greater than or equal to 10mm. Duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection. Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years or older, male and female Exclusion criteria: Duodenal or ampullary adenoma \<10mm Duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to provide Informed Consent Less than 18 years old Allergy to Octreotide
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Florida Hospital, Orlando, Florida, United States
Contact Details
Name: Robert Hawes, MD
Affiliation: AdventHealth
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
